Home » Stocks » AMYT

Amryt Pharma PLC (AMYT)

Stock Price: $11.18 USD -0.15 (-1.32%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 413.82M
Revenue (ttm) 186.47M
Net Income (ttm) -92.17M
Shares Out 35.88M
EPS (ttm) -2.80
PE Ratio n/a
Forward PE 67.57
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $11.18
Previous Close $11.33
Change ($) -0.15
Change (%) -1.32%
Day's Open 11.18
Day's Range 11.10 - 11.44
Day's Volume 32,017
52-Week Range 10.06 - 15.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6

2 weeks ago - GlobeNewsWire

Publication of Circular to Amryt S hareholders in relation to the acquisition of Chiasma, Inc . , and p osting of Annual Report and Notice s of General Meeting s

4 weeks ago - GlobeNewsWire

Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.

1 month ago - GlobeNewsWire

Amryt Pharma PLC (NASDAQ:AMYT LON:AMYT) said the US Food and Drug Administration had confirmed its New Drug Application (NDA) for Oleogel-S10 does not require an Advisory Committee meeting.   Oleogel-S1...

1 month ago - Proactive Investors

FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting

1 month ago - GlobeNewsWire

Amryt (AMYT) is seeking approval for Oleogel-S10 as a potential treatment for patients with rare and distressing genetic skin disorder, epidermolysis bullosa.

1 month ago - Zacks Investment Research

The FDA has granted priority review status to Amryt Pharma's (NASDAQ: AMYT) marketing application seeking approval for Oleogel-S10 to treat Epidermolysis Bullosa (EB). Oleogel-S10 is a potential treatme...

1 month ago - Benzinga

Amryt Pharma PLC (NASDAQ:AMYT; AIM:AMYT) was granted a priority review of its new drug application for Oleogel-S10 by the US Food & Drug Administration with a decision expected on or before November 30....

1 month ago - Proactive Investors

Amryt Pharma PLC (NASDAQ:AMYT; AIM:AMYT) has been granted a priority review of its new drug application for Oleogel-S10 by the US drugs watchdog with a decision expected on or before November 30. The US...

1 month ago - Proactive Investors

FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

1 month ago - GlobeNewsWire

What the company does Amryt Pharma PLC (LON:AMYT) sells and develops orphan drugs used to treat rare diseases with two products on the market. Last year, Amryt acquired US group Aegerion Pharmaceuticals...

1 month ago - Proactive Investors

Amryt Pharma PLC's (NASDAQ:AMYT, LON:AMYT) new drug application for its potential treatment for epidermolysis bullosa (EB) has been approved by the US regulator. The Food and Drug Administration (FDA) a...

1 month ago - Proactive Investors

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chiasma, Inc. (Nas...

Other stocks mentioned: CHMA
2 months ago - Business Wire

NEW YORK, May 5, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Chiasma, Inc. (NASDAQ: CHMA) and its board of directors concerning the proposed acquisition ...

Other stocks mentioned: CHMA
2 months ago - PRNewsWire

NEW YORK, May 5, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Chiasma, Inc. ("Chiasma" or the "Company"...

Other stocks mentioned: CHMA
2 months ago - PRNewsWire

Amryt Pharma PLC (LON:AMYT NASDAQ:AMYT)  is to merge with fellow Nasdaq-listed biotech Chiasma Inc (NASDAQ:CHMA) through an all-share deal that will create a leading specialist in rare and orphan diseas...

Other stocks mentioned: CHMA
2 months ago - Proactive Investors

A mryt R e ports Record Q1 2021 Financial and Operating Results

2 months ago - GlobeNewsWire

- Combined business will have three approved commercial products , lomitapide ( Lojuxta ®/ Juxtapid ®), metreleptin ( Myalept ®/ Myalepta ®) , octreotide ( MYCAPSSA ®) and a robust clinical pipeline

2 months ago - GlobeNewsWire

DUBLIN, Ireland, and Boston MA, April 15, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatme...

3 months ago - GlobeNewsWire

DUBLIN, Ireland, and Boston MA, April 6, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatmen...

3 months ago - GlobeNewsWire

Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said it hopes its gel designed to treat a rare skin disease will win fast-track approval from the US Food & Drug Administration after finishing the rolling compl...

3 months ago - Proactive Investors

Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said has completed the rolling submission process that it hopes will end with the fast-track sign-off by the US Food & Drug Administration for its gel to treat a...

3 months ago - Proactive Investors

DUBLIN, Ireland, and Boston MA, March 31, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatme...

3 months ago - GlobeNewsWire

Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said it was ‘encouraged' by data from an investigator-sponsored study of lomitapide in Familial Chylomicronaemia Syndrome (FCS). Expert lipidologists in Italy ad...

3 months ago - Proactive Investors

Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said it was ‘encouraged' by data from an investigator-sponsored study of lomitapide in Familial Chylomicronaemia Syndrome (FCS). Expert lipidologists in Italy ad...

3 months ago - Proactive Investors

Amryt Pharma PLC (LON:AMYT, NASDAQ:AMYT) said the European Union regulator will now begin the formal review process for its potential treatment for a rare genetic skin disorder with no currently approve...

3 months ago - Proactive Investors

Amryt Pharma PLC (LON:AMYT, NASDAQ:AMYT) said it has received positive feedback from the American drug regulator as it seeks sign-off for its Myalept drug for use in patients with partial lipodystrophy ...

4 months ago - Proactive Investors

Amryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy

4 months ago - GlobeNewsWire

Rare diseases specialist Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said the French authorities have signed off its drug Myalepta for reimbursement. The Ministry of Social Affairs and Health said it will ...

4 months ago - Proactive Investors

Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)

4 months ago - GlobeNewsWire

Amryt Pharma plc

4 months ago - GlobeNewsWire

Exercise of Options and Total Voting Rights

4 months ago - GlobeNewsWire

Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights

4 months ago - GlobeNewsWire

Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said it has signed an agreement with Medison Pharma Canada, which will distribute the former's Myalepta drug in the country. It completes the multi-regional dist...

4 months ago - Proactive Investors

Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

4 months ago - GlobeNewsWire

Amryt Pharma PLC (LON:AMYT, NASDAQ:AMYT) said it expects to continue strong sales growth for 2021 after reporting a first underlying profit and strong cash flow for the past year. The biopharma company,...

4 months ago - Proactive Investors

Amryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021

5 months ago - GlobeNewsWire

Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel

5 months ago - GlobeNewsWire

Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales

6 months ago - GlobeNewsWire

Amryt Granted Orphan Drug Designation by the FDA for AP103

7 months ago - GlobeNewsWire

Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia

7 months ago - GlobeNewsWire

TR-1: S tandard form for notification of major holdings

7 months ago - GlobeNewsWire

TR-1: S tandard form for notification of major holdings

7 months ago - GlobeNewsWire

Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil

7 months ago - GlobeNewsWire

Amryt Announces $40m Private Placement with Leading Biotech Investors

7 months ago - GlobeNewsWire

AMRYT REPORTS RECORD Q3 2020 RESULTS

8 months ago - GlobeNewsWire

AMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA

8 months ago - GlobeNewsWire

AMRYT PHARMA PLC

9 months ago - GlobeNewsWire

AMRYT PHARMA PLC

9 months ago - GlobeNewsWire

About AMYT

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinica... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2015
Stock Exchange
NASDAQ
Ticker Symbol
AMYT
Full Company Profile

Financial Performance

In 2020, Amryt Pharma's revenue was $182.61 million, an increase of 214.17% compared to the previous year's $58.12 million. Losses were -$104.53 million, 65.9% more than in 2019.

Financial Statements